Advice

Following a full submission.

Teriparatide (Forsteo®) is accepted for restricted use within NHS Scotland for the treatment of established (severe) osteoporosis in post-menopausal women.

This medicine should be restricted to initiation by specialists experienced in the treatment of osteoporosis following assessment of fracture risk including measurement of BMD. It is the first product to be licensed specifically for established (severe) post-menopausal osteoporosis. It has shown efficacy in reducing vertebral and non-vertebral fractures in post-menopausal women with prior vertebral fractures, particularly in a sub-group with documented severe osteoporosis. At the recommended daily dose it is expensive but appears to be cost-effective in women with proven osteoporosis who have developed fractures.

Download detailed advice21KB (PDF)

Download

Medicine details

Medicine name:
Teriparatide (Forsteo®)
SMC ID:
71/03
Indication:
Established (severe) osteoporosis in postmenopausal women
Pharmaceutical company
Eli Lilly and Company Ltd
BNF chapter
Endocrine system
Submission type
Full
Status
Superseded
Date advice published:
08 December 2003